Compares a dual-targeted CAR-T therapy with standard treatments for relapsed multiple myeloma
Tests AZD0120, a CAR-T cell therapy, in adults with relapsed or refractory multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Key facts
- Where
- Calgary, Montreal, Toronto, and Vancouver, CanadaSee the 4 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that has come back or stopped responding after 1 to 3 earlier treatments. It compares a CAR-T therapy (AZD0120) with standard drug combinations.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Multiple myeloma with measurable disease and worsening (progression) during or after the latest treatment. ECOG performance status 0 to 1.
- Earlier treatment
- 1 to 3 earlier lines of treatment, including an IMiD and either a PI or a CD38 antibody. No earlier BCMA treatment, CAR-T or CAR-NK therapy, or T-cell engager therapy.
- Biomarker or test result
- Measurable disease: serum M-protein of 1 g/dL or more, or urine M-protein of 200 mg/24h or more, or serum free light chain of 10 mg/dL (100 mg/L) or more with an abnormal ratio.
Main reasons for not taking part
- Myeloma in the brain or spinal fluid area (CNS) now or in the past
- Primary amyloidosis, active plasma cell leukaemia, Waldenstrom macroglobulinemia or POEMS syndrome
- Myeloma that never responded to any earlier treatment
- Earlier donor (allogeneic) stem cell transplant, or own (autologous) stem cell transplant within 12 weeks of randomization
- Significant neurological or psychiatric condition
Read by machine on 9 November 2026.
Where in Canada
- Calgary, AlbertaHospital not named in the registryNot yet recruiting
- Montreal, QuebecHospital not named in the registryTaking people
- Toronto, OntarioHospital not named in the registryTaking people
- Vancouver, British ColumbiaHospital not named in the registryNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07391657
- Record updated
- 29 September 2026
- Original description
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab, pomalidomide, and dexamethasone], PVd [pomalidomide, bortezomib and dexamethasone], or Kd [carfilzomib and dexamethasone]) in participants with RRMM.Read full original descriptionShow less
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab, pomalidomide, and dexamethasone], PVd [pomalidomide, bortezomib and dexamethasone], or Kd [carfilzomib and dexamethasone]) in participants with RRMM.
Inclusion: Age ≥ 18 years; Documented diagnosis of multiple myeloma according to the IMWG diagnostic criteria; Documented evidence of measurable disease:; Serum M-protein level ≥ 1 g/dL; Urine M-protein level ≥ 200 mg/24h; Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio; Documented evidence of PD by IMWG 2016 criteria based on investigator's determination during or after the most recent line of therapy. Participants with only 1 prior line of therapy must have progressed within 47 months of a stem cell transplant, or if not transplanted, then within 42 months of starting initial therapy; Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody. Participant must have undergone at least 2 complete cycles of treatment for each line of therapy, unless PD was the best response to the line of therapy; Eligible to receive at least one of the standard regimens (DKd, PVd, DPd, or Kd) as determined by the Investigator; ECOG performance status score of 0 to 1; Adequate hematology and chemistry laboratory values:; Haemoglobin ≥ 8.0 g/dL; Absolute neutrophil count ≥ 1 × 10\^9/L (1000 per mm3); Platelet count ≥ 75 × 10\^9/L (75000 per mm3) in participants with < 50% of bone marrow nucleated cells are plasma cells or ≥ 50 × 10\^9/L (50000 per mm3) in participants with ≥ 50% of bone marrow nucleated cells are plasma cells; Absolute lymphocyte count ≥ 300/µL (0.3 × 109/L); Total bilirubin ≤ 1.5 × ULN in the absence of Gilbert's syndrome or ≤ 3 × ULN if the participant has Gilbert's syndrome. AST and ALT≤ 3.0 × ULN. CrCl by Cockcroft and Gault method ≥ 30 mL/minute.
Exclusion: Known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM; Participants with primary refractory MM (failed to generate at least a minimal response to any prior therapy); Previously received any prior BCMA-targeted treatment; Previously received CAR-T or CAR-NK therapy directed at any target; Previously received T-cell engager therapy directed at any target; Previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of randomization; Primary amyloidosis, active plasma cell leukaemia, Waldenstrom macroglobulinemia or Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin (POEMS) syndrome; Significant neurological or psychiatric condition; Significant medical condition that places the participant at an unacceptable risk for treatment-related complications.